ArticleLeukemia2019
Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.Blood cancer journal · 2022Pooled it
- ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.International journal of cancer · 2026Article
- Article
- Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.Blood cancer journal · 2024Article
- Article
- It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.Blood advances · 2023Review
- A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohort.Scientific reports · 2022Article
- Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.Frontiers in immunology · 2022Review
- Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016.Scientific reports · 2021Article
- Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?Advances in hematology · 2021Review
- Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance.Blood advances · 2020Article
- Article
- Genetic predisposition for multiple myeloma.Leukemia · 2020Review
- Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.Blood · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30737484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.